Maternal Metabolic Control and Perinatal Outcome in Women With Gestational Diabetes Mellitus Treated With Lispro or Aspart Insulin
Comparison with regular insulin
- Graziano Di Cianni, MD,
- Laura Volpe, MD,
- Alessandra Ghio, MD,
- Cristina Lencioni, MD,
- Ilaria Cuccuru, MD,
- Luca Benzi, MD and
- Stefano Del Prato, MD
- From the Section of Diabetes, Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy
- Address correspondence to Dr. Graziano Di Cianni, Department of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, Ospedale di Cisanello, Via Paradisa, 2, 56126 Pisa. E-mail: dicianni{at}immr.med.unipi.it
Gestational diabetes mellitus (GDM) is associated with increased risk of maternal and neonatal morbidity with macrosomia being the most common neonatal complication (1). The risk of macrosomia and/or disproportionate fetal growth is closely related to 1-h postprandial glucose concentration (2).
Therefore, the treatment of GDM should be aimed at normalizing maternal glycemia including the early postprandial response. Insulin therapy is needed whenever strict normoglycemia cannot be achieved by medical nutritional therapy alone (3). Because of their pharmacokinetic properties, short-acting insulin analogs (Insulin Aspart [ASP] and Insulin Lispro [LIS]) could be more effective in pregnancy than human regular insulin (HI) (4). Nevertheless, data …
